Positive Phase III Data Set Stage For Japan Imeglimin Filing

Partners Poxel and Sumitomo Dainippon confirm Japan filing plans for novel glimin antidiabetic following positive top-line Phase III results, and cast an eye towards market positioning.

Doctor checks blood glucose monitor to meet with diabetic patients.
Imeglimin Edges Towards Japan Filing • Source: Shutterstock

French metabolic disorders company Poxel SA and Asia partner Sumitomo Dainippon Pharma Co. Ltd. (SDP) say they remain on track for a planned Japanese approval submission sometime in 2020 for imeglimin, following new top-line Phase III results for the novel antidiabetic.

The plan could potentially lead to a 2021 launch for the oral glimin class molecule in what may become the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia